Ewa Mrózek

2.5k total citations
45 papers, 1.6k citations indexed

About

Ewa Mrózek is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, Ewa Mrózek has authored 45 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 13 papers in Cancer Research and 7 papers in Genetics. Recurrent topics in Ewa Mrózek's work include Cancer Treatment and Pharmacology (16 papers), Breast Cancer Treatment Studies (10 papers) and Cancer Cells and Metastasis (5 papers). Ewa Mrózek is often cited by papers focused on Cancer Treatment and Pharmacology (16 papers), Breast Cancer Treatment Studies (10 papers) and Cancer Cells and Metastasis (5 papers). Ewa Mrózek collaborates with scholars based in United States, India and Switzerland. Ewa Mrózek's co-authors include MA Caligiuri, Paul Anderson, Charles L. Shapiro, Rachel M. Layman, Bhuvaneswari Ramaswamy, Janice K. Kiecolt‐Glaser, Ronald Glaser, William B. Malarkey, Charles F. Emery and Jeanette M. Bennett and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Blood.

In The Last Decade

Ewa Mrózek

45 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ewa Mrózek United States	20	756	552	257	217	182	45	1.6k
Martin Buess Switzerland	16	409 0.5×	411 0.7×	168 0.7×	324 1.5×	185 1.0×	31	1.3k
Tanya E. Keenan United States	20	1.1k 1.5×	423 0.8×	365 1.4×	425 2.0×	388 2.1×	43	2.1k
Koen De Geest United States	22	693 0.9×	267 0.5×	200 0.8×	458 2.1×	258 1.4×	44	2.3k
Jocelyn Sendecki United States	19	448 0.6×	136 0.2×	196 0.8×	191 0.9×	68 0.4×	35	1.2k
Sarah E. Strandjord United States	21	361 0.5×	236 0.4×	226 0.9×	340 1.6×	104 0.6×	43	1.6k
Theodore S. Johnson United States	16	475 0.6×	1.2k 2.2×	107 0.4×	333 1.5×	70 0.4×	27	2.0k
Amy Lin United States	23	436 0.6×	258 0.5×	466 1.8×	470 2.2×	177 1.0×	80	1.3k
Christian Kersten Norway	21	745 1.0×	203 0.4×	210 0.8×	330 1.5×	194 1.1×	68	1.3k
Vicky Jones United States	19	2.0k 2.7×	724 1.3×	553 2.2×	455 2.1×	643 3.5×	34	2.9k
Hanzhong Li China	22	354 0.5×	276 0.5×	655 2.5×	545 2.5×	346 1.9×	202	2.1k

Countries citing papers authored by Ewa Mrózek

Since Specialization

Citations

This map shows the geographic impact of Ewa Mrózek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ewa Mrózek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ewa Mrózek more than expected).

Fields of papers citing papers by Ewa Mrózek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ewa Mrózek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ewa Mrózek. The network helps show where Ewa Mrózek may publish in the future.

Co-authorship network of co-authors of Ewa Mrózek

This figure shows the co-authorship network connecting the top 25 collaborators of Ewa Mrózek. A scholar is included among the top collaborators of Ewa Mrózek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ewa Mrózek. Ewa Mrózek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Quiroga, Dionisia, Robert Wesolowski, Brooke Benner, et al.. (2024). An Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer. Cancer Control. 31. 2925668237–2925668237. 3 indexed citations

Sardesai, Sagar, Mohamed Badawi, Ewa Mrózek, et al.. (2020). A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer. Investigational New Drugs. 38(5). 1400–1410. 24 indexed citations

Vargo, Craig, Michael Berger, Gary Phillips, & Ewa Mrózek. (2016). Occurrence and characterization of everolimus adverse events during first and subsequent cycles in the treatment of metastatic breast cancer. Supportive Care in Cancer. 24(7). 2913–8. 3 indexed citations

Mrózek, Ewa, Rachel M. Layman, Bhuvaneswari Ramaswamy, et al.. (2014). Phase II Trial of Neoadjuvant Weekly Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Biweekly Bevacizumab Therapy in Women With Clinical Stage II or III HER2-Negative Breast Cancer. Clinical Breast Cancer. 14(4). 228–234. 29 indexed citations

Barginear, Myra F., Hyman B. Muss, Gretchen Kimmick, et al.. (2014). Breast cancer and aging: results of the U13 conference breast cancer panel. Breast Cancer Research and Treatment. 146(1). 1–6. 19 indexed citations

Damodaran, Senthil, Ewa Mrózek, David A. Liebner, & Kari Kendra. (2014). Focal Takotsubo Cardiomyopathy With High-Dose Interleukin-2 Therapy for Malignant Melanoma. Journal of the National Comprehensive Cancer Network. 12(12). 1666–1670. 13 indexed citations

Berger, Michael, Craig Vargo, Gary Phillips, et al.. (2014). Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Supportive Care in Cancer. 23(7). 2019–2024. 19 indexed citations

Berger, Michael, Marlo Blazer, Brooke Crawford, et al.. (2013). Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy. Supportive Care in Cancer. 21(10). 2845–2851. 19 indexed citations

Poi, Ming, Michael Berger, Maryam B. Lustberg, et al.. (2013). Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review. Supportive Care in Cancer. 21(10). 2679–2686. 29 indexed citations

10.

Layman, Rachel M., Amy S. Ruppert, Ewa Mrózek, et al.. (2013). Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer. Cancer Chemotherapy and Pharmacology. 71(5). 1183–1190. 31 indexed citations

11.

Yang, Xiangyu, Ewa Mrózek, Maryam B. Lustberg, et al.. (2012). Microcirculatory fraction (MCFI) as a potential imaging marker for tumor heterogeneity in breast cancer. Magnetic Resonance Imaging. 30(8). 1059–1067. 2 indexed citations

12.

Mrózek, Ewa, et al.. (2012). Phase II Trial of Exemestane in Combination With Fulvestrant in Postmenopausal Women With Advanced, Hormone-Responsive Breast Cancer. Clinical Breast Cancer. 12(2). 151–156. 7 indexed citations

13.

Lustberg, Maryam B., Shubham Pant, Amy S. Ruppert, et al.. (2012). Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes. Cancer Chemotherapy and Pharmacology. 70(1). 49–56. 19 indexed citations

14.

Lustberg, Maryam B., Stephen P. Povoski, Weiqiang Zhao, et al.. (2011). Phase II Trial of Neoadjuvant Exemestane in Combination With Celecoxib in Postmenopausal Women Who Have Breast Cancer. Clinical Breast Cancer. 11(4). 221–227. 21 indexed citations

15.

Ramaswamy, Bhuvaneswari, Ewa Mrózek, J. Philip Kuebler, Tanios Bekaii‐Saab, & Eric H. Kraut. (2009). Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer. Investigational New Drugs. 29(2). 347–351. 23 indexed citations

16.

Mrózek, Ewa, Jill Kolesar, Donn C. Young, et al.. (2008). Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC). Annals of Oncology. 19(8). 1417–1422. 14 indexed citations

17.

Mrózek, Ewa, Bhuvaneswari Ramaswamy, Donn C. Young, et al.. (2006). Phase II Study of Weekly Docetaxel and Capecitabine in Patients with Metastatic Breast Cancer. Clinical Breast Cancer. 7(2). 141–145. 12 indexed citations

18.

Farag, Sherif S., Patrick Elder, Guido Marcucci, et al.. (2003). Radiation-free regimens result in similar outcomes of allogeneic hematopoietic progenitor cell transplantation in patients aged ≥50 years compared to younger adults with low-risk disease. Bone Marrow Transplantation. 31(2). 87–93. 9 indexed citations

19.

Fehniger, Todd A., Eric M. Bluman, Michelle M. Porter, et al.. (2000). Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy. Journal of Clinical Investigation. 106(1). 117–124. 87 indexed citations

20.

Mrózek, Krzysztof, Bogusław Nedoszytko, Małgorzata Babińska, et al.. (1990). Trisomy of chromosome 12 in a case of thecoma of the ovary. Gynecologic Oncology. 36(3). 413–416. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact